Each filer's latest filing for 135086106 since 12/18/2024, largest first.
| Filer | % of Class | Filed | ||
|---|---|---|---|---|
|
Bain Capital Integral Investors 2008, L.P.
13G/A
|
40.1% |
2/17/2026
Event 12/31/2025
|
||
| Bain Capital Integral Investors 2008, L.P. | 40.1% | |||
| BCPE Fund X Goose Holdings, L.P. | 0% | |||
|
Dani Reiss
13G/A
|
22.3% |
9/24/2026
Event 9/9/2026
|
||
| Dani Reiss | 22.3% | |||
| DTR LLC | 20.7% | |||
|
WBT Value Ltd
13G
|
13.3% |
10/26/2026
Event 10/26/2026
|
||
| WBT Value Ltd | 13.3% | |||
| Roger Luo | 13.3% | |||
|
FMR LLC
13G/A
|
8.5% |
11/5/2026
Event 9/30/2026
|
||
| FMR LLC | 8.5% | |||
| Abigail P. Johnson | 8.5% | |||
| Under 5%, checked the "5 percent or less" box, or amended by a later filing (6) | ||||
| Ilex Capital Partners (UK) LLP 13G | 4.1% |
5/14/2026
Event 3/31/2026
|
||
| Massachusetts Financial Services Co /MA/ 13G/A | 4.0% |
5/14/2025
Event 3/31/2025
|
||
|
Ameriprise Financial, Inc.
13G/A
|
3.8% |
11/14/2025
Event 9/30/2025
|
||
| Ameriprise Financial, Inc. | 3.8% | |||
| Ameriprise Financial Services, LLC | 3.8% | |||
|
Portolan Capital Management, LLC
13G/A
|
2.9% |
11/16/2026
Event 9/30/2026
|
||
| Portolan Capital Management, LLC | 2.9% | |||
| George McCabe | 2.9% | |||
|
Patient Capital Management, LLC
13G/A
|
1.6% |
8/14/2025
Event 6/30/2025
|
||
| Patient Capital Management, LLC | 1.6% | |||
| Patient Opportunity Trust, a series of Advisor Managed Portfolios | 0.7% | |||
|
Morgan Stanley
13G/A
|
0% |
1/8/2026
Event 12/31/2025
|
||
| Morgan Stanley | 0% | |||
| Morgan Stanley Investment Management Inc. | 0% | |||
| Morgan Stanley Institutional Fund, Inc. - International Advantage Portfolio | 0% | |||
| Period | Filers | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 101 | 20.9 M | $163M |
| 2026 Q2 | 115 | 24.5 M | $233M |
| 2026 Q1 | 118 | 28.1 M | $308M |
| 2025 Q4 | 135 | 28.7 M | $371M |
| 2025 Q3 | 123 | 28.4 M | $392M |
| 2025 Q2 | 119 | 31.8 M | $356M |
| 2025 Q1 | 113 | 30.9 M | $246M |
| 2024 Q4 | 120 | 33.4 M | $336M |
| 2024 Q3 | 134 | 36.7 M | $459M |
| 2024 Q2 | 127 | 39.2 M | $519M |
| 2024 Q1 | 136 | 40.1 M | $484M |
| 2023 Q4 | 135 | 45.6 M | $541M |
| 2023 Q3 | 125 | 51.5 M | $757M |
| 2023 Q2 | 135 | 52.3 M | $932M |
| 2023 Q1 | 148 | 57.2 M | $1.10B |
| 2022 Q4 | 154 | 49.9 M | $889M |
| 2022 Q3 | 146 | 45.7 M | $700M |
| 2022 Q2 | 150 | 47.0 M | $848M |
| 2022 Q1 | 149 | 46.8 M | $1.23B |
| 2021 Q4 | 160 | 45.8 M | $1.69B |
| 2021 Q3 | 146 | 47.7 M | $1.72B |
| 2021 Q2 | 157 | 49.9 M | $2.19B |
| 2021 Q1 | 166 | 50.0 M | $1.98B |
| 2020 Q4 | 168 | 56.4 M | $1.69B |
| 2020 Q3 | 160 | 52.5 M | $1.70B |
| 2020 Q2 | 145 | 52.4 M | $1.22B |
| 2020 Q1 | 155 | 53.8 M | $1.07B |
| 2019 Q4 | 193 | 63.2 M | $2.28B |
| 2019 Q3 | 188 | 62.9 M | $2.76B |
| 2019 Q2 | 201 | 57.2 M | $2.22B |
| 2019 Q1 | 240 | 57.0 M | $2.74B |
| 2018 Q4 | 213 | 54.2 M | $2.38B |
| 2018 Q3 | 179 | 42.3 M | $2.73B |
| 2018 Q2 | 179 | 42.8 M | $2.52B |
| 2018 Q1 | 139 | 32.7 M | $1.09B |
| 2017 Q4 | 139 | 30.3 M | $957M |
| 2017 Q3 | 110 | 29.4 M | $604M |
| 2017 Q2 | 125 | 29.2 M | $577M |
| 2017 Q1 | 71 | 15.8 M | $252M |
| 2016 Q1 | 1 | 431 | $21.0k |